Hey guys, check out this ICO Examiner article discussing how the United States Naval Air Systems Command (NAVAIR) is exploring using blockchain to track aircraft parts in conjunction with Indiana Technology and Manufacturing Companies (ITAMCO).

https://www.icoexaminer.com/ico-news/us-navy-explore-blockchain-supply-chain-solution/

Anyone who has to gauge logistical risk will see worth not just in the blockchain protocol layer that facilitates the source of value but also the application layer that is used to connect to the technology.

The OEL Foundation themselves are a non-profit organization open to enterprises in the supply chain and logistics industry who believe that measurable case studies will soon replace the concepts and proposals currently dominating the industry.

Codex is based off the Ethereum platform but its development progress hasn’t been hamstrung by issues to do with scalability. Unlike other blockchain ideas that rely on high-volume, low-value transactions, the opposite is true for Codex. High ETH transaction costs – which spiked to $0.49 last week – are far outweighed by the savings made with a shared, public registry.

Modifying Codex Records requires fees payable in CodexCoin. This is analogous to gas in Ethereum. It’s also similar to the 0x Protocol where makers and takers pay fees in ZRX (the 0x token) to relayers to exchange tokens. Operations to read data are completely free, but operations to create, update, and transfer Codex Records have an associated fee depending on the type of modification. For example, adding a lien on a registered item may cost more than a transfer of title operation. Fees will be used to replenish a community pool that is used for rewards. It is not intended that these fees should be burdensome for any one individual. Rather, they will be relevant for stakeholders who use the protocol in volume for commercial use, like app developers and auction houses.

Open Enterprise Logistics will run on a proof of stake blockchain concept, optimizing their chain across scalability, transparency/trust, data security, and sharing rewards.

Scalability: The OEL platform ensures consistent transaction speeds with minimal cost effects.

Transparency/Trust: OEL’s ecosystem provides a completely open platform through decentralization and blockchain technology, ensuring transparency and trust to all market makers.

Data Security: OEL provides full privacy and security of user data, abiding by regulations set forth in GDPR.

Sharing Rewards: OEL rewards supply chain market hitters when they share their supply chain data and locations through the distribution of their ICO token, OPN.

The Clintex CTi platform aims to drive cost efficiency by providing affordable clinical data analytics services.
Pharmaceutical companies gain deep insight into the operational and clinical aspects of their trials without the
necessity of major investment into backend technical infrastructure and data science expertise, whilst benefitting from the security of blockchain architecture.
The CTi platform distinguishes itself from other tools used in clinical trials by:

1. Bringing machine learning to clinical trial management;
2. Allowing for workflow management that “closes the loop”;
3. Enabling full audit-trail functionality to identify, action and resolve issues detected by the tool;
4. Eliminating the need for hardware costs to be borne by the client;
5. Introducing an attractive pay-per-use model for clients;
6. Applying powerful and insightful data analytics functionality across administrative, operational and clinical
functions in clinical trials;
7. Exploiting the immutability and interoperability of data filtered through the blockchain to create an
ecosystem that fosters collaboration across the entire pharmaceutical industry;
8. Being the first ever collaboration platform for clinical trials.

ClinTex CTi platform will be the first to bring a decentralised solution to the clinical trial  process, enabling pharmaceutical companies to maximise end-to-end efficiencies through the use of smart contracts, data sharing, operational and clinical visualisations, and predictive analytics using our decentralised applications.

There are 4 phases in the current clinical trials. In the first phase of a clinical trial, the proposed drug safety is tested  1/1 and those tests last for more than two months and usually involve a number of healthy volunteers who are paid to be
part of the trial. The aim of this study is to observe how would the human body react to the tested drug or device  and different dosages and intensity are included. The statistics showed the 70% of drugs/devices pass this phase.

The second phase tests the efficiency of the drug/device and usually lasts from several months to about two years.  The number of volunteers in this phase jumps to hundreds of people. Many of the studies conducted in this phase are  random and they are usually applied on two groups of people. The first group takes a dosage of the experimental  drug while the other group takes a standard medication while thinking that they're taking the actual experimental drug.  The researchers are unaware of the actual experiment too. This is done to observe the psychological effects and  human behavior. By gathering this information, the investigators deliver comparative information about the safety and  efficiency of the drug or device to pharmaceutical companies and the FDA. About 33.3% of the tested drugs or  devices go through phase I and II.

The third phase of clinical trials are randomized as well and they usually have several hundred to thousands of  volunteers. In this phase the scale of the testing is way bigger and testing a drug or device would take a minimum of  2 years or even more. By having a large number of volunteers, the investigators get a better understanding and more  details on the effectiveness, benefits, and the possible harmful or unwanted reactions. When a drug/device passes this  phase, pharmaceutical companies are able to request approval from the FDA to start marketing the drug.

The fourth phase and the last phase is named Post Marketing Surveillance Trial which is a study that starts after the  drug or the device is available for consumer use. There are three main objectives of this study, first pharmaceutical  companies compare the new drug or device to other existing drugs. Secondly, they observe the long-term effectiveness  of the drug on the patient's progress and life quality. Third, they determine the cost-effectiveness of the new drug  compared to existing or popular drugs. The results of this phase can lead to having the new drug or device taken off  the market, or some restrictions may apply when using the new medicine or tool.

The cost of running these clinical trials is now higher than ever, with expenses running at between $30 million and $70 million for a single Phase III trial.

Integrating Blockchain technology with Clinical trials will give the following benefits:

1: Security to the clinical data and protection from any alteration 

2: An immutable record that will show data and all changes in a consistent matter   

3: Past data that will show the complete history of clinical information

4: peer-2peer payments via smart contracts

5: Operation interoperability between several systems and data formats

6: Protection of privacy is possible. Blockchain technology allows adding and verifying records to an immutable ledger  without compromising the content of each record. 

7: Control of access to the content of each record by using encryption keys. The public key shows that the record  exists while the private key gives access to the content of the record.

Smart Containers transports temperature sensitive pharmaceuticals and food around the world in the safest way, eliminating temperature excursions on the way.

WHO & WEF estimate that 40% of all vaccines delivered worldwide are ineffective, since they have been transported in the wrong way. These products break down or even become harmful if the required temperature level is not maintained. Unfortunately, with medicine, it is more complex than with food: when medicine is “broken” it doesn’t change color or smell badly. Therefore it is very important to track the temperature along all the supply chain.

When it comes to food, they maintain the food transport conditions more accurately than any other player, resulting in better food quality and fresher produce. Team manages to do this in a more sustainable way than any other provider, because our containers are made of recycled material and are lighter than other vessels. In this way they manage to reduce our CO2 footprint bi 50%.

The blockchain application LOGI Chain will help us to create a more seamless, fully integrated logistics process, which will drive down our shipping costs significantly. It will automate the whole shipping process, which today is highly driven by manual intervention. Through smart contracts team will invoice shippings automatically in cryptocurrencies. This will create a new logistic ecosystem that will ultimately be joined by every player in the market and disrupt the logistics industry.

The Ethereum Virtual Machine (EVM) is the software that runs on the Ethereum network and allows for the creation
and development of different applications all on one platform. It has an unparalleled track record in hosting
decentralised applications which enable the execution of smart contracts, which parties can fulfil certain conditions
and validate those conditions automatically using code. Due to smart contracts’ self-executing nature, single-party
manipulation is averted because control over the execution of the smart contract does not fall into the hands of a single party. Autonomy, trust, speed, and safety are Ethereum’s key strengths and these will be pivotal to the CTi ecosystem. While there are other DLT platforms in the space that promise a superior transaction speed per second, these promises have not yet been realised. Ethereum’s proven, viable and ready-to-use blockchain is the perfect platform on which to host the CTi eco-system.

The SMARC Token is a token conferring profit participation rights. Because of its economic function the Swiss Financial Market Supervisory Authority qualifies the SMARC Token as a so called “Asset Token”. However, SMARC Tokens do not represent or confer any ownership right or stake, share or security or equivalent rights of participation in Smart Containers and its corporate affiliates. It neither provides the Tokenholder with a conversion right into shares or other equity of Smart Containers nor any other right whatsoever, other than the rights mentioned in the Terms of Token Sale.  It is therefore not equivalent to a security and does not qualify as a security according to current Swiss law.

An impressive aspect of the OEL Foundation is the team’s dedication to maintaining industry standards and best practices in the development of the system. With the help of blockchain technology, the organization will eliminate disputes by confirming records on the blockchain the moment it is verified e.g after a satisfied business receiving their goods on time.

The OEL Foundation’s solutions are also designed in a such a way that benefits the transport industry as a whole instead of only benefiting one or two major companies.

As stated in their one-pager: There is currently no competitor product where data analytics and machine learning are used to monitor and control clinical trial costs. What is significant is that they are not simply referring to the blockchain and decentralized application space, but to the medical space

Hey guys, these are the business objectives currently underway:

- Continue scaling of SkyCell in both B2B and B2C
- Establish FoodGuardians
- Establish the of LOGI CHAIN Foundation
- Regularly evaluate organic scaling vs. M&A
- Evaluate IPO at relevant time

While on the crypto side, exchange listing is the next goal.

This recently published article features Cofounder and CEO of Codex Protocol, Mark Lurie's comments on the future of ICO and crypto.


https://www.coinspeaker.com/2018/09/05/idacb-will-promote-new-high-tech-unicorn-via-bloomberg-and-reuters-on-the-cryptocurrency-market/

Security and privacy is not a problem in the ecosystem as the OEL Foundation complies with industry standards and best practices to ensure that users have full control over their personal data in addition to protecting the data as much as possible.

The OEL Foundation will also introduce a rewards-based model where users are rewarded in OPN Tokens (the platform’s official utility token) for sharing their supply chain data, a move that incentivizes participants fairly for their positive contributions to the platform.

OEL Foundation has come up with the idea of having an open source decentralized infrastructure for the sake of logistics applications. OEL Foundation aims at improving the efficiency and the authentication in the logistic ecosystem significantly.

Hello guys

Global Blockchain Consortium team recently took to Twitter to express how delighted they were to have ClinTex CTi as a new partner, tweeting out this poster along with the announcement.

https://twitter.com/gbconsortium/status/1033489434749100032

The folks at TechBullion recently caught up with Neill Barron, Director of Clinical Data Analytics at ClinTex to discuss ClinTex, Clinical Trial problems and Blockchain Technology.

Read More https://www.techbullion.com/interview-with-neill-barron-director-of-clinical-data-analytics-at-clintex/

As a proof-of-stake blockchain, the OEL Enterprise Architecture is optimised across four key criteria:

1. Low costs and consistent transaction speed – For scalability
2. Data confidentiality – For enterprise-grade applications
3. Rewarding data sharing – For bridging the gap between the physical supply chain and the decentralized ledger
4. Open collaborative governance – For ensuring standards required of all participants in the supply chain.